TERT启动子突变与WHO II级和III级脑膜瘤预后不良相关
该研究纳入87例非典型(N=72)和间变性(N=15)脑膜瘤患者,采用PCR检测TERT启动子C228T和C250T突变,比较突变型与野生型预后。TERT启动子突变见于4例WHO II级和2例WHO III级脑膜瘤,与更短的无进展生存期相关(中位PFS 12.5 vs. 26个月,p=.004),单因素分析中TERT启动子突变对总生存期(p=.009)和无进展生存期有强预后价值。作者认为TERT启动子突变应被视为识别高危患者的临床相关预后因素。
要点
- 87例WHO II级和III级脑膜瘤中,6例检出TERT启动子突变(4例II级、2例III级)。
- TERT启动子突变型中位PFS 12.5个月,野生型26个月(p=.004)。
- 单因素分析中TERT启动子突变对总生存期有强预后价值(p=.009)。
核心结论
- 在WHO II级和III级脑膜瘤中,TERT启动子突变的存在与更短的无进展生存期和总生存期相关。
- 作者认为在这些肿瘤中,TERT启动子突变应被视为识别高危患者的临床相关预后因素。
研究设计与样本
- 纳入接受手术切除的侵袭性脑膜瘤患者,共87例,其中非典型脑膜瘤72例、间变性脑膜瘤15例。
- 采用PCR方法检测TERT启动子区域C228T和C250T突变,将患者分为TERT突变组与TERT野生型组。
- 使用分子和组织学因素进行单因素分析。
主要发现
- TERT启动子区域突变见于4例WHO II级和2例WHO III级脑膜瘤。
- TERT启动子突变型中位无进展生存期12.5个月 vs. TERT野生型26个月(p=.004)。
- 单因素分析中,TERT启动子突变对总生存期有强预后价值(p=.009),对无进展生存期亦有强预后价值。
临床怎么用
- 作者认为,在WHO II级和III级脑膜瘤中,TERT启动子突变应被视为识别高危患者的临床相关预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Transcriptional activating mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene occur at high frequency in various types of solid tumors and have also been reported for meningiomas. Especially for atypical and anaplastic meningiomas, the prognostic relevance of TERT promoter mutation is yet unclear. The present study aimed to analyze the frequency of TERT promoter mutation and define its long-term prognostic significance beyond clinical and histological factors in a cohort of meningiomas WHO grade II and III. METHODS: Patients undergoing surgical resection of aggressive meningiomas were included. Analysis for C228T and C250T mutation in the TERT promoter region was performed using PCR method. Patients were stratified into two groups (TERT mutated vs. TERT wild type). Univariate analysis was conducted using molecular and histological factors. RESULTS: 87 patients with atypical (N = 72) and anaplastic meningiomas (N = 15) were included in the study. TERT promoter region was found to be mutated in 4 WHO grade II and 2 WHO grade III meningiomas. TERT promoter mutation was associated with shorter progression free survival than TERT wild type meningiomas (median PFS 12.5 vs. 26 months, p = .004). In the univariate analysis, TERT promoter mutation had a strong prognostic value on overall survival (p = .009) and progression free survival. CONCLUSIONS: Presence of TERT promoter mutation is associated with shorter progression free survival and overall survival in meningiomas WHO grade II and III. In these tumors, TERT promoter mutation should be considered as a clinically relevant prognostic factor to identify high risk patients.
引用
- Biczok A, Kraus T, Suchorska B, et al. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neurooncol. 2018. PMID: 29808339. doi:10.1007/s11060-018-2912-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。